Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of UCB4019 in Healthy Subjects
NCT02873767Phase 1Completed
- Sponsor
- UCB
- Start
- Aug 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) (5 arms), sponsored by UCB. Primary endpoint: Incidence of treatment emergent adverse events. Started Aug 2016; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02873767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873767.